# Barricaid (United States)

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/barricaid-united-states/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 52 |
| Citations | 2,250 |
| City | Woburn |
| Country | US |
| Description | Barricaid (United States) is a research organisation in Woburn, US. OpenAlex records 60 works and 2,250 citations for it. 42 researchers list it as their most recent affiliation. |
| Homepage | https://www.barricaid.com/ |
| OpenAlex ID | https://openalex.org/I4210095601 |
| Region | Massachusetts |
| Researchers | 42 |
| ROR ID | https://ror.org/00a4gmh33 |
| Type | company |
| Works | 60 |

## University papers

- [National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report](https://scholariq.org/papers/national-institutes-of-health-consensus-development-project-on-criteria-for/)
- [Risk factors for acute GVHD and survival after hematopoietic cell transplantation](https://scholariq.org/papers/risk-factors-for-acute-gvhd-and-survival-after-hematopoietic-cell/)
- [Ibrutinib for chronic graft-versus-host disease after failure of prior therapy](https://scholariq.org/papers/ibrutinib-for-chronic-graft-versus-host-disease-after-failure-of-prior-therapy/)
- [Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study](https://scholariq.org/papers/belumosudil-for-chronic-graft-versus-host-disease-after-2-or-more-prior-lines-of/)
- [Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study](https://scholariq.org/papers/efficacy-and-safety-of-lifileucel-a-one-time-autologous-tumor-infiltrating/)
- [Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/chronic-myeloid-leukemia-version-1-2019-nccn-clinical-practice-guidelines-in/)

## University top topics

Showing 8 of 25.

- [Spine and Intervertebral Disc Pathology](https://scholariq.org/topics/spine-and-intervertebral-disc-pathology/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Musculoskeletal pain and rehabilitation](https://scholariq.org/topics/musculoskeletal-pain-and-rehabilitation/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Pelvic and Acetabular Injuries](https://scholariq.org/topics/pelvic-and-acetabular-injuries/)
- [Facial Rejuvenation and Surgery Techniques](https://scholariq.org/topics/facial-rejuvenation-and-surgery-techniques/)
- [Alzheimer's disease research and treatments](https://scholariq.org/topics/alzheimer-s-disease-research-and-treatments/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.